ErbB Receptors
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) (NCT02695290) | Boehringer Ingelheim | 2016-03-17 |
| Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older (NCT02514174) | Boehringer Ingelheim | 2015-08-18 |
Track ErbB Receptors automatically
Every clearance here is in the API, with alerts when new ones post.